SOPHiA GENETICS (SOPH) said Tuesday it is expanding its partnership with AstraZeneca (AZN).

Under the multiyear collaboration, AstraZeneca will use SOPHiA's AI Factories to generate evidence on the efficacy, value, and impact of treatments for some types of breast cancer, the company said.

The project will also back the potential development of an AI-supported model to optimize outcomes for people in treatment for breast cancer, SOPHiA said.

Financial terms were not disclosed.